

Sector: Health Care
Sub-Industry: Health Care Services
Peer Group: Home Health Specialized Services

Summary: This company provides home health nursing services in two operating segments, Visiting Nurse and Personal Care. AFAM has an approximate 0.05% weighting in the **S&P SmallCap**

Quantitative Evaluations

S&P Quality Ranking : B

D	C	B-	B	B+	A-	A	A+
---	---	----	----------	----	----	---	----

S&P Fair Value Rank: 5-

1	2	3	4	5
---	---	---	---	----------

Lowest Highest

Fair Value Calc: \$42.70 (Undervalued)

S&P Investability Quotient Percentile

33%

1 Lowest Highest 100

AFAM scored lower than 67% of all companies for which an S&P Report is available.

Volatility: High

Low	Average	High
-----	---------	-------------


Technical Evaluation: BEARISH

Since April, 2011, the technical indicators for AFAM have been BEARISH.

Relative Strength Rank: Weak

15

1 Lowest Highest 99



Options: CBOE

Investment Strategy

Key financial variables to consider in assessing the investment merits of an industrial company are the following:

Sales: What is the trend? Is future sales growth expected to be greater than the past 5-year and 9-year growth average? Accelerating sales growth ultimately provides the fuel behind earnings growth.

Net Margin: As a key measure of company profitability, a rising net margin assesses management capability to wring out more net income from incremental sales.

% LT Debt to Capitalization: A rising percentage implies greater financial risk, all else being equal. Rising debt leverage without a concomitant rise in Return on Equity should raise warning signals of potential cash flow problems. Percentages above 40%-50% should also be considered a warning.

% Return on Equity: A key performance measurement of capital efficiency assesses what investment returns management can earn on a company's existing capital base. A sustained percentage above 20% is considered above average.

Key Growth Rates and Averages

Past Growth Rate (%)	1 Year	3 Year	5 Year	9 Year
Sales	13.12	36.96	38.81	20.09
Net Income	24.38	57.09	66.46	45.63

Ratio Analysis (Average)

Net Margin	9.11	8.37	7.14	4.92
%LT Debt to Capitalization	0.72	8.03	17.51	25.68
% Return on Equity	18.55	21.37	21.39	17.85

Revenues/Earnings Data Fiscal year ending Dec. 31

Revenues (Million \$)	2011	2010	2009	2008	2007	2006
1Q	82.59	81.78	69.20	39.03	31.95	20.79
2Q	--	85.61	74.85	48.70	32.71	21.85
3Q	--	84.90	76.29	58.71	32.06	22.95
4Q	--	84.64	78.02	66.17	35.41	26.23
Year	--	336.9	297.9	212.6	132.1	91.81

Earnings per Share (\$)	2011	2010	2009	2008	2007	2006
1Q	0.61	0.80	0.68	0.45	0.31	0.17
2Q	--	0.89	0.72	0.50	0.35	0.18
3Q	--	0.85	0.73	0.57	0.34	0.20
4Q	--	0.74	0.74	0.62	0.39	0.26
Year	--	3.28	2.87	2.17	1.40	0.80

Next earnings report expected: Early August

Historical GAAP earnings are as reported.

Key Stock Statistics

Average Daily Volume	0.080 mil.	Beta	0.90
Market Capitalization	\$0.299 Bil.	Trailing 12 Month EPS	\$3.09
Institutional Holdings (%)	60	12 Month P/E	10.4
Shareholders of Record	374	Current Yield (%)	Nil

Value of \$10,000 Invested five yrs Ago : **\$27,901**

Please read the required disclosures and Reg. AC certification on the last page of this report.

This report was prepared by Standard & Poor's Quantitative Services.


Redistribution or reproduction is prohibited without written permission. Copyright ©2011 The McGraw-Hill Companies, Inc.

Wall Street Opinions/Average (Mean) Opinion: Hold

	No. of Ratings	% of Total	1 Mo. Prior	3 Mo. Prior
Buy	1	14	1	1
Buy/Hold	0	0	0	0
Hold	6	86	7	6
Weak Hold	0	0	0	0
Sell	0	0	0	0
No Opinion	0	0	0	0
Total	7	100	8	7

Insider Moves

Insider Buys Insider Sells Price History



Dividend Data

No Dividend Data Available

Company Financials Fiscal year ending Dec. 31

Per Share Data & Valuation Ratios (\$)	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001
Tangible Book Value	7.24	3.86	NM	NM	NA	2.20	1.54	1.29	0.83	1.33
Cash Flow	3.60	3.19	2.37	1.56	0.99	0.78	0.39	0.75	0.95	0.60
Earnings	3.28	2.87	2.17	1.40	0.80	0.56	0.29	0.25	0.25	0.39
Dividends	Nil	Nil	Nil	Nil	NA	Nil	Nil	Nil	Nil	Nil
Payout Ratio	Nil	Nil	Nil	Nil	NA	Nil	Nil	Nil	Nil	Nil
Prices:High	44.12	47.90	53.85	26.59	NA	8.93	7.43	4.73	8.25	8.17
Prices:Low	23.50	14.91	16.60	13.69	NA	5.31	3.68	2.00	2.33	1.69
P/E Ratio:High	14	17	25	19	NA	16	25	19	34	21
P/E Ratio:Low	7	5	8	10	NA	10	12	8	9	4

Income Statement Analysis (Million \$)

Revenue	337	298	213	132	91.8	75.6	86.8	86.9	85.8	59.8
Operating Income	54.6	44.8	29.7	14.9	8.04	5.28	5.47	5.25	5.94	5.85
Depreciation	2.91	2.38	1.52	0.93	1.00	1.19	2.46	2.55	3.84	1.27
Interest Expense	0.27	0.80	1.15	0.84	NA	0.11	0.45	0.66	0.81	0.71
Pretax Income	51.4	41.3	27.1	13.1	7.09	4.24	2.52	1.92	2.13	3.86
Effective Tax Rate	NA	40%	39%	40%	40%	32%	39%	34%	37%	42%
Net Income	30.7	24.7	16.4	7.81	4.27	2.88	1.53	1.27	1.34	2.24

Balance Sheet & Other Financial Data (Million \$)

Cash	47.9	19.4	1.30	0.47	4.13	7.20	0.42	0.90	0.97	1.93
Current Assets	100	64.8	43.6	20.5	19.3	18.1	15.2	17.8	20.1	22.6
Total Assets	220	183	161	67.4	53.4	30.5	28.1	33.0	36.8	35.9
Current Liabilities	27.7	25.3	37.3	15.0	12.1	8.84	8.66	8.08	9.62	10.6
Long Term Debt	1.33	2.80	27.1	16.4	13.0	1.12	5.08	12.3	15.9	14.1
Common Equity	182	149	94.8	34.8	27.7	20.1	13.6	12.3	10.1	10.4
Total Capital	185	152	126	52.0	40.8	21.3	18.7	24.6	26.0	24.5
Capital Expenditures	2.61	2.13	1.48	0.59	0.86	0.56	0.56	1.51	2.74	2.09
Cash Flow	33.6	27.4	17.9	8.75	5.28	4.07	3.99	3.81	5.18	3.51
Current Ratio	3.6	2.6	1.2	1.4	1.6	2.1	1.8	2.2	2.1	2.1
% Long Term Debt of Capitalization	0.7	1.8	22.3	31.5	31.9	5.3	27.2	49.9	61.2	57.6
% Net Income of Revenue	9.1	8.3	7.7	5.9	4.7	3.8	1.8	1.5	1.6	3.8
% Return on Assets	15.2	14.4	14.4	12.9	10.2	10.3	5.1	3.6	3.7	NM
% Return on Equity	18.6	20.3	25.3	25.0	17.9	17.9	11.8	11.3	12.7	NM


Data as orig. reptd; bef. results of disc opers/spec. items. Per share data adj. for stk. divs. as of ex-div date. NA-Not Available. NM-Not Meaningful. NR-Not Ranked.

Office: 9510 Ormsby Station Rd Ste 300, Louisville, KY, 40223-5016
Tel: 502-891-1000
Email: <http://www.almost-family.com/contact.htm>
Website: <http://www.almost-family.com>
CEO, Chrmn & Pres: **W. B. Yarmuth**

SVP, Chief Acctg Officer, Investor Contact, Treas, Secy & CFO: **C. S. Guenther**
Dir: **H. M. Altman, Jr., S. Bing, J. D. Goldberg, D. G. McClinton, W. E. Reed, III, T. Wilburn, W. B. Yarmuth**
General Counsel: **J. Perchik**

Chief Admin Officer: **P. T. Lyles**
CIO: **M. Spurlock**
Founded: **1985**
Domicile: **Delaware**
Employees: **6,400**

Stock Performance



	Company(%)	Industry(%)	S&P 1500(%)
YTD Return	-16.6	11.4	6.7
One Year Return	-18.6	15.5	16.3
Three Year Return (% Annualized)	12.4	12.3	-0.9
Five Year Return (% Annualized)	22.8	14.3	1.1
Value of \$10,000 Invested 5 Years Ago	\$27,901	\$19,496	\$10,565

Sub-Industry Outlook

Our fundamental outlook for the health care services sub-industry for the next 12 months is positive. We think most services, including home health care, rehabilitation services, clinical laboratory services and dialysis, will continue to benefit from favorable demographic trends.

We are optimistic on clinical labs. Although weak employment markets adversely affected physician office visits in 2010 by an estimated 5%-7%, we believe the market has stabilized, and we expect to see a modest increase in office visits in 2011. As a result, we believe labs will benefit from higher volumes, an increase in tests per requisition, and an increase in esoteric/genomic tests, which we see spurring revenue growth beyond low to mid-single digit levels. Meanwhile, in lieu of a health care reform tax, clinical labs agreed to a 1.75% cut in the Medicare clinical lab fee schedule in each of the next five years starting in 2011. However, we believe the expansion of coverage to an additional 32 million Americans via health care reform starting in 2014 will outweigh the impact of lower reimbursement rates.

We are positive on the dialysis group, as we view newly implemented bundled dialysis payment rates as manageable. The majority of dialysis providers took an immediately implemented 4.1% rate cut rather than a 3.1% cut if phased in over four years, to mitigate the burden of implementing the new system. Over the longer term, we expect revenue per treatment to rise, given lower drug costs for providers. We do, however, expect sustained reimbursement rate pressure due to regulatory focus on containing health care costs. We are also favorably inclined toward respiratory therapy

services. We believe that while Medicare reimbursement issues may continue to pressure sales growth, the impact on revenues could be mitigated through expense management and market share gains.

We remain positive on pharmacy benefit managers (PBMs), which help managed care organizations, governments and employers control drug spending. While the soft economy has reduced pharmaceutical consumption, we believe it is spurring generic drug utilization. We also see PBMs increasingly benefiting from the billions of dollars in branded drugs slated to lose patent protection over the next few years. Increased generic drug usage would increase PBMs' profitability. Also, the increase in mail-order pharmacy penetration aids profitability.


Year to date through May 6, the S&P Health Care Services Index increased 8.8%, while the S&P 1500 Composite Index advanced 6.6%.

--Jeffrey Loo, CFA

Stock Performance

GICS Sector: Health Care
Sub-Industry: Health Care Services

Based on S&P 1500 Indexes
Month-end Price Performance as of 04/29/11




NOTE: All Sector & Sub-Industry information is based on the Global Industry Classification Standard (GICS)

Sub-Industry : Health Care Services Peer Group*: Home Health Specialized Services

Peer Group	Stock Symbol	Stk.Mkt. Cap. (Mil. \$)	Recent Stock Price(\$)	52 Week High/Low(\$)	Beta	Yield (%)	P/E Ratio	Fair Value Calc.(\$)	Quality Ranking	S&P IQ %ile	Return on Revenue (%)	LTD to Cap (%)
Almost Family	AFAM	299	32.03	40.76/23.50	0.90	Nil	10	42.70	B	33	9.1	0.7
Allied Healthcare Intl	AHCI	113	2.59	3.10/1.86	0.97	Nil	13	NA	B-	22	3.6	0.3
Continuicare Corp	CNU	302	4.99	5.80/3.25	0.64	Nil	13	6.60	B-	77	7.1	NA
Gentiva Health Svcs	GTIV	764	25.08	30.17/18.93	0.60	Nil	15	33.10	B-	30	4.0	60.8
Lincare Holdings	LNCR	2,911	30.74	33.45/22.55	0.62	2.6	16	35.50	B+	92	10.9	33.1

NA-Not Available NM-Not Meaningful NR-Not Rated. *For Peer Groups with more than 15 companies or stocks, selection of issues is based on market capitalization.

Analysts' Recommendations



Of the total 8 companies following AFAM, 7 analysts currently publish recommendations.

	No. of Ratings	% of Total	1 Mo. Prior	3 Mos. Prior
Buy	1	14	1	1
Buy/Hold	0	0	0	0
Hold	6	86	7	6
Weak Hold	0	0	0	0
Sell	0	0	0	0
No Opinion	0	0	0	0
Total	7	100	8	7

Wall Street Consensus Estimates



Fiscal Years	Avg Est.	High Est.	Low Est.	# of Est.	Est. P/E
2012	2.74	2.99	2.45	7	11.7
2011	2.74	2.96	2.47	7	11.7
2012 vs. 2011	0%	▲ 1%	▼ -0.8%	0%	0%
Q2'12	0.64	0.69	0.59	7	50.0
Q2'11	0.66	0.73	0.60	7	48.5
Q2'12 vs. Q2'11	▼ -3%	▼ -5%	▼ -2%	0%	▲ 3%

A company's earnings outlook plays a major part in any investment decision. Standard & Poor's organizes the earnings estimates of over 2,300 Wall Street analysts, and provides their consensus of earnings over the next two years. This graph shows the trend in analyst estimates over the past 15 months.

Wall Steet Consensus Opinion

HOLD

Companies Offering Coverage

- Avondale Partners LLC
- Bb&t Capital Markets
- Jefferies & Co.
- Macquarie Research
- RBC Capital Markets
- Robert W. Baird & Co., Inc.
- Stephens Inc.
- Suntrust Robinson Humphrey

Wall Street Consensus vs. Performance

For fiscal year 2011, analysts estimate that AFAM will earn \$2.74. For the 1st quarter of fiscal year 2011, AFAM announced earnings per share of \$0.61, representing 22% of the total annual estimate. For fiscal year 2012, analysts estimate that AFAM's earnings per share will remain unchanged with this year's estimate at \$2.74

Glossary

S&P Quality Ranking - Growth and stability of earnings and dividends are deemed key elements in establishing S&P's quality ranking for common stocks, which are designed to capsize the nature of this record in a single symbol. It should be noted that, however, that the process also takes into consideration certain adjustments and modifications deemed desirable in establishing such rankings. The final score for each stock is measured against a scoring matrix determined by analysis of the scores of a large and representative sample of stocks. The range of scores in the array of this sample has been aligned with the following ladder of rankings:

A+	Highest	B	Lower
A	High	B-	Below Average
A-	Above Average	C	Lowest
B+	Average	D	In Reorganization
NR	Not Ranked		

S&P Fair Value Rank - Using S&P's exclusive proprietary quantitative model, stocks are ranked in one of five groups, ranging from Group 5, listing the most undervalued stocks, to Group 1, the most overvalued issues. Group 5 stocks are expected to generally outperform all others. A positive (+) or negative (-) Timing Index is placed next to the Fair Value ranking to further aid the selection process. A stock with a (+) added to the Fair Value Rank simply means that this stock has a somewhat better chance to outperform other stock with the same Fair Value Rank. A stock with a (-) has a somewhat lesser chance to outperform other stocks with the same Fair Value Rank. The Fair Value rankings imply the following: 5-Stock is significantly undervalued; Fair Value Rank. A stock with a (-) has a somewhat lesser chance to outperform other stocks with the same Fair Value Rank. The Fair Value rankings imply the following: 5-Stock is significantly undervalued; 4-Stock is moderately undervalued; 3-Stock is fairly valued; 2-Stock is modestly overvalued; 1-Stock is significantly overvalued.

Funds From Operations (FFO) - FFO is Funds from Operations and equal to a REIT's net income, excluding gains or losses from sales of property, plus real estate depreciation.

Fair Value Calculation - The current price at which a stock should sell today as calculated by S&P's computers using our quantitative model based on the company's earnings, growth potential, return on equity relative to the S&P 500 and its industry group, price to book ratio history, current yield relative to the S&P 500, and other factors.

Investability Quotient (IQ) - The IQ is a measure of investment desirability. It serves as an indicator of potential medium-to-long-term return and as a caution against downside risk. The measure takes into account variables such as technical indicators, earnings estimates, liquidity, financial ratios and selected S&P proprietary measures.

Standard & Poor's IQ Rationale:
Almost Family

	Raw Score	Max Value
Proprietary S&P Measures	29	115
Technical Indicators	16	40
Liquidity/Volatility Measures	16	20
Quantitative Measures	24	75
IQ Total	85	250

Volatility - Rates the volatility of the stock's price over the past year.

Technical Evaluation - In researching the past market history of prices and trading volume for each company, S&P's computer models apply special technical methods and formulas to identify and project price trends for the stock.

Relative Strength Rank - Shows, on a scale of 1 to 99, how the stock has performed versus all other companies in S&P's universe on a rolling 13-week basis.

Global Industry Classification Standard (GICS) - An industry classification standard, developed by Standard & Poor's in collaboration with Morgan Stanley Capital International (MSCI). GICS is currently comprised of 10 Sectors, 24 Industry Groups, 67 Industries, and 147 Sub-Industries.

Dividends on American Depository Receipts (ADRs) and American Depository Shares (ADSs) are net of taxes (paid in the country of origin).

Required Disclosures

All of the views expressed in this research report reflect Standard & Poor's Quantitative Services' research models regarding the above issuer and securities. No part of Standard & Poor's Quantitative Services compensation was, is or will be directly or indirectly, related to the specific recommendations or views expressed in this research report.

This report was prepared by Standard & Poor's Quantitative Services ("SPQS"). SPQS is affiliated with various entities that may perform non-investment banking services for this company. Each such affiliate operates independently from each other.

Additional information is available upon request.

Disclaimer

This material is based upon information that we consider to be reliable, but neither SPQS nor its affiliates warrant its completeness or accuracy, and it should not be relied upon as such. Assumptions, opinions and estimates constitute our judgment as of the date of this material and are subject to change without notice. Past performance is not indicative of future results.

This material is not intended as an offer or solicitation for the purchase or sale of any security or other financial instrument. Securities, financial instruments or strategies mentioned herein may not be suitable for all investors. This material does not take into account your particular investment objectives, financial situations or needs and is not intended as a recommendation of particular securities, financial instruments or strategies to you. Before acting on any recommendation in this material, you should consider whether it is suitable for your particular circumstances and, if necessary, seek professional advice.